AGP Picks
View all

Yemen Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.

Press releases published on October 1, 2026

Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
Helus Pharma Announces Completion of Legal Name Change
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies
Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course
Caspian Therapeutics Appoints Manasi Jaiman, M.D., M.P.H., and Elizabeth Mily to Board of Directors
MitoRx Therapeutics presents new preclinical data on MTRX31, demonstrating restored mitochondrial density, at the 62nd EASD Annual Meeting
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Yemen Health Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.